On January $1,2023,$ Pulaski, Incorporated, acquired a $60$ percent interest in the common stock of Sheridan, Incorporated, for $\backslash (\backslash$$ $392,400\backslash ).$ Sheridan's book value on that date consisted of common stock of $\backslash (\backslash$$ $100,000\backslash )$ and retained earnings of $\backslash (\backslash$$ $231,900\backslash ).$ Also, the acquisition$-$date fair value of the $40$ percent noncontrolling interest was $\backslash (\backslash$$ $261,600\backslash ).$ The subsidiary held patents $($with a $10-$year remaining life$)$ that were undervalued within the company's accounting records by $\backslash (\backslash$$ $81,700\backslash )$ and also had unpatented technology $(15$year estimated remaining life$)$ undervalued by $\backslash (\backslash$$ $57,000\backslash ).$ Any remaining excess acquisition$-$date fair value was assigned to an indefinitelived trade name. Since acquisition, Pulaski has applied the equity method to its Investment in Sheridan account. At year$-$end, there are no intra$-$entity payables or receivables.

Intra$-$entity inventory sales between the two companies have been made as follows:

The individual financial statements for these two companies as of December $31,2024,$ and the year then ended follow:

Note: Parentheses indicate a credit balance. Required A

Show how Pulaski determined the $\backslash (\backslash$$ $429,006\backslash )$ Investment in Sheridan account balance. Assume that Pulaski defers $100$ percent of downstream intra$-$entity profits against its share of Sheridan's income.

Note: Amounts to be deducted should be indicated with a minus sign.